A validated model of serum anti-müllerian hormone from conception to menopause.

Anti-Müllerian hormone (AMH) is a product of growing ovarian follicles. The concentration of AMH in blood may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve, and be of value in predicting reproductive lifespan. A full description of AMH production up to the menopaus...

Full description

Bibliographic Details
Main Authors: Thomas W Kelsey, Phoebe Wright, Scott M Nelson, Richard A Anderson, W Hamish B Wallace
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3137624?pdf=render
_version_ 1818572837112250368
author Thomas W Kelsey
Phoebe Wright
Scott M Nelson
Richard A Anderson
W Hamish B Wallace
author_facet Thomas W Kelsey
Phoebe Wright
Scott M Nelson
Richard A Anderson
W Hamish B Wallace
author_sort Thomas W Kelsey
collection DOAJ
description Anti-Müllerian hormone (AMH) is a product of growing ovarian follicles. The concentration of AMH in blood may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve, and be of value in predicting reproductive lifespan. A full description of AMH production up to the menopause has not been previously reported.By searching the published literature for AMH concentrations in healthy pre-menopausal females, and using our own data (combined n = 3,260) we have generated and robustly validated the first model of AMH concentration from conception to menopause. This model shows that 34% of the variation in AMH is due to age alone. We have shown that AMH peaks at age 24.5 years, followed by a decline to the menopause. We have also shown that there is a neonatal peak and a potential pre-pubertal peak. Our model allows us to generate normative data at all ages.These data highlight key inflection points in ovarian follicle dynamics. This first validated model of circulating AMH in healthy females describes a transition period in early adulthood, after which AMH reflects the progressive loss of the NGF pool. The existence of a neonatal increase in gonadal activity is confirmed for females. An improved understanding of the relationship between circulating AMH and age will lead to more accurate assessment of ovarian reserve for the individual woman.
first_indexed 2024-12-15T00:02:58Z
format Article
id doaj.art-f79f12cf69f1477087384f420ac58fae
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-15T00:02:58Z
publishDate 2011-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-f79f12cf69f1477087384f420ac58fae2022-12-21T22:42:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0167e2202410.1371/journal.pone.0022024A validated model of serum anti-müllerian hormone from conception to menopause.Thomas W KelseyPhoebe WrightScott M NelsonRichard A AndersonW Hamish B WallaceAnti-Müllerian hormone (AMH) is a product of growing ovarian follicles. The concentration of AMH in blood may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve, and be of value in predicting reproductive lifespan. A full description of AMH production up to the menopause has not been previously reported.By searching the published literature for AMH concentrations in healthy pre-menopausal females, and using our own data (combined n = 3,260) we have generated and robustly validated the first model of AMH concentration from conception to menopause. This model shows that 34% of the variation in AMH is due to age alone. We have shown that AMH peaks at age 24.5 years, followed by a decline to the menopause. We have also shown that there is a neonatal peak and a potential pre-pubertal peak. Our model allows us to generate normative data at all ages.These data highlight key inflection points in ovarian follicle dynamics. This first validated model of circulating AMH in healthy females describes a transition period in early adulthood, after which AMH reflects the progressive loss of the NGF pool. The existence of a neonatal increase in gonadal activity is confirmed for females. An improved understanding of the relationship between circulating AMH and age will lead to more accurate assessment of ovarian reserve for the individual woman.http://europepmc.org/articles/PMC3137624?pdf=render
spellingShingle Thomas W Kelsey
Phoebe Wright
Scott M Nelson
Richard A Anderson
W Hamish B Wallace
A validated model of serum anti-müllerian hormone from conception to menopause.
PLoS ONE
title A validated model of serum anti-müllerian hormone from conception to menopause.
title_full A validated model of serum anti-müllerian hormone from conception to menopause.
title_fullStr A validated model of serum anti-müllerian hormone from conception to menopause.
title_full_unstemmed A validated model of serum anti-müllerian hormone from conception to menopause.
title_short A validated model of serum anti-müllerian hormone from conception to menopause.
title_sort validated model of serum anti mullerian hormone from conception to menopause
url http://europepmc.org/articles/PMC3137624?pdf=render
work_keys_str_mv AT thomaswkelsey avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT phoebewright avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT scottmnelson avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT richardaanderson avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT whamishbwallace avalidatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT thomaswkelsey validatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT phoebewright validatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT scottmnelson validatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT richardaanderson validatedmodelofserumantimullerianhormonefromconceptiontomenopause
AT whamishbwallace validatedmodelofserumantimullerianhormonefromconceptiontomenopause